Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2020 | Upcoming updates in the MPN field at ASH 2020

Prithviraj Bose, MD, University of Texas MD Anderson Cancer Center, Houston, TX, shares his excitement for upcoming clinical trial updates in the myeloproliferative neoplasms (MPNs) field at ASH 2020. There will be updates on PTG-300, a novel hepcidin mimetic, for polycythemia vera (PV). Additionally, Dr Bose highlights the EXPLORER trial (NCT02561988) of avapritinib in patients with advanced systemic mastocytosis (ASM), in particular, the pure pathologic response (PPR) assessment. PPR criterion is particularly important for increasing the number of patients evaluated in future ASM trials. Lastly, Dr. Bose goes on to discuss the upcoming trials in myelofibrosis. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.


Prithviraj Bose, MD, has received honoraria from Incyte Corporation and Celgene Corporation (now BMS); has received consulting fees from Incyte Corporation, Celgene Corporation, Blueprint Medicines, CTI BioPharma and Kartos Therapeutics; and has received research funding from Incyte Corporation, Celgene Corporation, Blueprint Medicines, CTI BioPharma, Kartos Therapeutics, Constellation Pharmaceuticals, Astellas, Pfizer, NS Pharma and Promedior.